Staphylococcus aureus colonization and nosocomial infections: Implications for prevention

Current Infectious Disease Reports

Volumn 6, Issue 6, 2004, Pages 435-441

  Polgreen, Philip M ^b   Herwaldt, Loreen A ^a  

^a UNIVERSITY OF IOWA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLICIN; BETA LACTAM ANTIBIOTIC; CEFALEXIN; CLINDAMYCIN; COCAINE; COTRIMOXAZOLE; CRYSTAL VIOLET; DECONGESTIVE AGENT; ERYTHROMYCIN; GENTAMICIN; LYSOSTAPHIN; METICILLIN; MINOCYCLINE; PENICILLIN G; PLACEBO; PROBIOTIC AGENT; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STEROID; TEA TREE OIL; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; CLINICAL TRIAL; DRUG USE; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; REVIEW; RISK FACTOR; RISK REDUCTION; STAPHYLOCOCCUS AUREUS;

EID: 10244234169     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-004-0062-x     Document Type: Review

References (80)

1. Diekema DJ: Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001, 32(Suppl 2): 114-S132.
2. Lowy FD: Staphylococcus aureus infections. N Engl J Med 1998, 339:520-532.
3. Skinner D: Significance of bacteremia caused by Staphylococcus aureus. Arch Intern Med 1941, 68:851-875.
4. Diekema DJ, Beckmann SE, Chapin KC, et al.: Epidemiology and outcome of nosocomial and community-onset blood-stream infection. J Clin Microbiol 2003, 41:3655-3660.
5. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA: Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002, 162: 229-2235.
6. Wisplinghoff H, Bischoff T, Tallent SM, et al.: Nosocomial blood-stream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317.
7. von C Eiff, Becker K, Machka K, et al.: Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med 2001, 344:11-16.
8. Ena J, Boelaert JR, Boyken LD, et al.: Epidemiology of Staphylococcus aureus infections in patients on hemodialysis. Infect Control Hosp Epidemiol 1994, 15:78-81.
9. Luzar MA, Coles GA, Faller B, et al.: Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. N Engl J Med 1990, 322:505-509.
10. Perl TM, Cullen JJ, Wenzel RP, et al.: Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 2002, 346:1871-1877.
11. Williams REO: Healthy carriage of Staphylococcus aureus: its prevalence and importance. Bacteriol Rev 1963, 27: 6-71.
12. Kluytmans JA, van Belkum A, Verbrugh H: Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997, 10:505-520.
13. Noble WC: Carriage of Staphylococcus aureus in random samples of a normal population. J Hyg (Lond) 1967, 65: 67-573.
14. Casewell MW: The carrier state: methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1986, 18(Suppl A):1-12.
15. Reagan DR, Doebbeling BN, Pfaller MA, et al.: Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med 1991, 114:101-106.
16. Parras F, Guerrero MC, Bouza E, et al.: Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1995, 39:175-179.
17. Vandenbergh MF, Verbrugh HA: Carriage of Staphylococcus aureus: epidemiology and clinical relevance. J Lab Clin Med 1999, 133:525-534.
18. Nahmias AJ, Lepper MH, Hurst V, Mudd S: Epidemiology and treatment of chronic staphylococcal infections in the household. Am J Pub Health 1962, 52:1828-1843.
19. Hoeger PH, Lenz W, Boutonnier A, Fournier JM: Staphylococcal skin colonization in children with atopic dermatitis: prevalence, persistence, and transmission of toxigenic and nontoxigenic strains. J Infect Dis 1992, 165:1064-1068.
20. Tuazon CU, Perez A, Kishaba T, Sheagren JN: Staphylococcus aureus among insulin-injection diabetic patients: an increased carrier rate. JAMA 1975, 231:1272.
21. Sissolak D, Geusau A, Heinze G, et al.: Risk factors for nasal carriage of Staphylococcus aureus in infectious disease patients, including patients infected with HIV, and molecular typing of colonizing strains. Eur J Clin Microbiol Infect Dis 2002, 21: 8-96.
22. Yu VL, Goetz A, Wagener M, et al.: Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med 1986, 315:91-96.
23. Pujol M, Pena C, Pallares R, et al.: Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. Am J Med 1996, 100: 09-516.
24. Tuazon CU, Sheagren JN: Increased rate of carriage of Staphylococcus aureus among narcotic addicts. J Infect Dis 1974, 129:725-727.
25. Berman DS, Schaefler S, Simberkoff MS, Rahal JJ: Staphylococcus aureus colonization in intravenous drug abusers, dialysis patients, and diabetics. J Infect Dis 1987, 155:829-831.
26. Gittelman PD, Jacobs JB, Lebowitz AS, Tierno PM Jr: Staphylococcus aureus nasal carriage in patients with rhinosinusitis. Laryngoscope 1991, 101:733-737.
27. White A, Smith J: Nasal reservoir as the source of extranasal staphylococci. Antimicrob Agents Chemother 1963, 3:679-683.
28. White A: Increased infection rates in heavy nasal carriers of coagulase-positive staphylococci. Antimicrob Agents Chemother 1963, 3:667-670.
29. Kalmeijer MD, van Nieuwland-Bollen E, Bogaers-Hofman D, de Baere GA: Nasal carriage of Staphylococcus aureus is a major risk factor for surgical-site infections in orthopedic surgery. Infect Control Hosp Epidemiol 2000, 21:319-323.
30. Kluytmans JAJW, Mouton JW, Ijzerman EP: Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis 1995, 171:216-219.
31. Nsouli KA, Lazarus M, Schoenbaum SC: Bacteremic infection in hemodialysis. Arch Intern Med 1979, 139:1255-1258.
32. Chow JW, Yu VL: Staphylococcus aureus nasal carriage in hemodialysis patients: its role in infection and approaches to prophylaxis. Arch Intern Med 1989, 149:1258-1262.
33. Dobkin JF, Miller MH, Steigbigel NH: Septicemia in patients on chronic hemodialysis. Ann Intern Med 1978, 88: 8-33.
34. Quarles LD, Rutsky EA, Rostand SG: Staphylococcus aureus bacteremia in patients on chronic hemodialysis. Am J Kid Dis 1985, 6:412-419.
35. Barcenas CG, Fuller TJ, Elms J, et al.: Staphylococcal sepsis in patients on chronic hemodialysis regimens: intravenous treatment with vancomycin given once weekly. Arch Intern Med 1976, 136:1131-1134.
36. Mennes PA, Gilula LA, Anderson CB, et al.: Complications associated with arteriovenous fistulas in patients undergoing chronic hemodialysis. Arch Intern Med 1978, 138: 117-1121.
37. Kaplowitz LG, Comstock JA, Landwehr DM, et al.: A prospective study of infections in hemodialysis patients: patient hygiene and other risk factors for infection. Infect Control Hosp Epidemiol 1988, 9:534-541.
38. Francioli P, Masur H: Complications of Staphylococcus aureus bacteremia: occurrence in patients undergoing long-term hemodialysis. Arch Intern Med 1982, 142:1655-1658.
39. Mathews M, Shen FH, Lindner A, Sherrard DJ: Septic arthritis in hemodialysis patients. Nephron 1980, 25: 7-91.
40. Moxley GF, Moffatt TL, Falls WF Jr: Hemodialysis-related osteomyelitis. South Med J 1980, 73:376-379.
41. Martin AM: The aetiology and management of shunt infections in patients on intermittent haemodialysis. Proc Eur Dial Transplant Assoc 1967, 4:67-72.
42. Herwaldt LA: Reduction of Staphylococcus aureus nasal carriage and infection in dialysis patients. J Hosp Infect 1998, 40:S13-S23.
43. Oxton LL, Zimmerman SW, Roecker EB, Wakeen M: Risk factors for peritoneal dialysis-related infections. Perit Dial Int 1994, 14:137-144.
44. Piraino B, Perlmutter JA, Holley JL, Bernardini J: Staphylococcus aureus peritonitis is associated with Staphylococcus aureus nasal carriage in peritoneal dialysis patients. Perit Dial Int 1992, 13:S332-S334.
45. Perez-Fontan M, Garcia-Falcon T, Rosales M, et al.: Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long-term results. Am J Kidney Dis 1993, 22:708-712.
46. Lye WC, Leong SO, van der Straaten J, Lee EJ: Staphylococcus aureus CAPD-related infections are associated with nasal carriage. Adv Perit Dial 1994, 10:163-165.
47. Davies SJ, Ogg CS, Cameron JS, et al.: Staphylococcus aureus nasal carriage, exit-site infection and catheter loss in patients treated with continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1989, 9:61-64.
48. Sesso R, Draibe S, Castelo A, et al.: Staphylococcus aureus skin carriage and development of peritonitis in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 1989, 31:264-268.
49. Pignatari A, Pfaller M, Hollis R, et al.: Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis. J Clin Microbiol 1990, 28:1898-1902.
50. Mulligan ME, Murray-Leisure KA, Ribner BS, et al.: Methicillin-resistant Staphylococcus aureus: a consensus review of the microbioology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 1993, 94:313-328.
51. Doebbeling BD, Breneman DL, Neu HC, et al.: Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group. Clin Infect Dis 1993, 17:466-474.
52. Boelaert JR, De Smedt RA, De Baere YA, et al.: The influence of calcium mupirocin nasal ointment on the incidence of Staphylococcus aureus infections in haemodialysis patients. Nephrol Dial Transplant 1989, 4:278-281.
53. Kluytmans JA, Manders MJ, van Bommel E, Verbrugh H: Elimination of nasal carriage of Staphylococcus aureus in hemodialysis patients. Infect Control Hosp Epidemiol 1996, 17:793-797.
54. The Mupirocin Study Group: Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis. J Am Soc Nephrol 1996, 7:2403-2408.
55. Tacconelli E, Carmeli Y, Aizer A, et al.: Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis. Clin Infect Dis 2003, 37:1629-1638.
56. Kluytmans JA, Mouton JW, VandenBergh MF, et al.: Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 1996, 17:780-785.
57. Cimochowski GE, Harostock MD, Brown R, et al.: Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics. Ann Thorac Surg 2001, 71:1572-1579.
58. Gernaat-van der Sluis AJ, Hoogenboom-Verdegaal AM, Edixhoven PJ, Spies-van Rooijen NH: Prophylactic mupirocin could reduce orthopedic wound infections: 1,044 patients treated with mupirocin compared with 1,260 historical controls. Acta Orthop Scand 1998, 69:412-414.
59. Wertheim HF, Vos MC, Ott A, et al.: Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in nonsurgical patients: a randomized study. Ann Intern Med 2004, 140:419-425.
60. Herwaldt LA, Cullen JJ, French P, et al.: Preoperative risk factors for nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 2004, 25:481-484.
61. Diekema DJ, Dodgson KJ, Sigurdardottir B, Pfaller MA: Rapid detection of antimicrobial-resistant organism carriage: an unmet clinical need. J Clin Microbiol 2004, 42:2879-2883.
62. Paule SM, Pasquariello AC, Hacek DM, et al.: Direct detection of Staphylococcus aureus from adult and neonate nasal swab specimens using real-time polymerase chain reaction. J Mol Diagn 2004, 6:191-196.
63. Huletsky A, Giroux R, Rossbach V, et al.: New real-time PCR assay for rapid detection of methicillin-resistant Staphylococcus aureus directly from specimens containing a mixture of staphylococci. J Clin Microbiol 2004, 42:1875-1884.
64. Shrestha NK, Shermock KM, Gordon SM, et al.: Predictive value and cost-effectiveness analysis of a rapid polymerase chain reaction for preoperative detection of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 2003, 24:327-333.
65. Miller MA, Dascal A, Portnoy J, Mendelson J: Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 1996, 17:811-813.
66. Cookson BD: The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother 1998, 41:11-18.
67. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, et al.: Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002, 39:337-341.
68. Upton A, Lang S, Heffernan H: Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotoc resistance. J Antimicrob Chemother 2003, 51:613-617.
69. Walker ES, Levy F, Shorman M, et al.: A decline in mupirocin resistance in methicillin-resistant Staphylococcus aureus accompanied administrative control of prescriptions. J Clin Microbiol 2004, 42:2792-2795.
70. Cutler RR, Wilson P: Antibacterial activity of a new, stable, aqueous extract of allicin against methicillin-resistant Staphylococcus aureus. Br J Biomed Sci 2004, 61:71-74.
71. Hurdle JG, O'Neill AJ, Chopra I: Anti-staphylococcal activity of indolmycin, a potential topical agent for control of staphylococcal infections. J Antimicrob Chemother 2004, 54: 49-552.
72. Natarajan S, Williamson D, Grey J, et al.: Healing of an MRSA-colonized, hydroxyurea-induced leg ulcer with honey. J Dermatolog Treat 2001, 12:33-36.
73. Miorin PL, Levy Junior NC, Custodio AR, et al.: Antibacterial activity of honey and propolis from Apis mellifera and Tetragonisca angustula against Staphylococcus aureus. J Appl Microbiol 2003, 95:913-920.
74. Okano M, Noguchi S, Tabata K, Matsumoto Y: Topical gentian violet for cutaneous infection and nasal carriage with MRSA. Int J Dermatol 2000, 39:942-944.
75. Saji M, Taguchi S, Uchiyama K, et al.: Efficacy of gentian violet in the eradication of methicillin-resistant Staphylococcus aureus from skin lesions. J Hosp Infect 1995, 31:225-228.
76. Dryden MS, Dailly S, Crouch M: A randomized, controlled trial of tea tree topical preparations versus a standard topical regimen for the clearance of MRSA colonization. J Hosp Infect 2004, 56:283-286.
77. Caelli M, Porteous J, Carson CF, et al.: Tea tree oil as an alternative topical decolonization agent for methicillin-resistant Staphylococcus aureus. J Hosp Infect 2000, 46:236-237.
78. Kokai-Kun JF, Walsh SM, Chanturiya T, Mond JJ: Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob Agents Chemother 2003, 47:1589-1597.
79. von Eiff C, Kokai-Kun JF, Becker K, Peters G: In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from anterior nares and blood. Antimicrob Agents Chemother 2003, 47:3613-3615.
80. Climo MW, Ehlert K, Archer GL: Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001, 45:1431-1437.